(Press-News.org) At 11 a.m. EDT on Oct. 8, Otto strengthened into a hurricane, becoming the eighth hurricane of the Atlantic Ocean season. NASA's Aqua satellite and the NOAA GOES-13 satellite captured images of Otto as he intensified.
Otto had maximum sustained winds near 75 mph, and the National Hurricane Center in Miami, Fla. noted that some strengthening is possible before it weakens on Saturday, Oct. 9. Otto was located about 445 miles south of Bermuda near 25.9 North and 64.0 West. It was moving east-northeast near 17 mph, and had a minimum central pressure of 979 millibars.
On Oct. 7 at 1729 UTC (1:29 p.m. EDT) NASA's Aqua satellite passed over Otto and the Atmospheric Infrared Sounder (AIRS) instrument captured an infrared image of its cloud temperatures. The image showed that the highest, coldest thunderstorm cloud tops colder than -65 Fahrenheit were around Otto's center and throughout the large band of strong thunderstorms extending from the southeast of Otto's circulation. That band of strong thunderstorms brought heavy rainfall on the already soaked areas of the northern Leeward Islands, the Virgin Islands, and Puerto Rico.
This morning, Otto developed a well-defined center, covered by dense overcast. There's a large curved band of showers and thunderstorms over the southeastern quadrant which continues to bring the heavy rainfall to the northern Leeward Islands, Virgin Islands, Puerto Rico and Dominican Republic today.
That large band of showers and thunderstorms extending from Otto's southeastern quadrant was apparent on infrared imagery from the Geostationary Operation Environmental Satellite, GOES-13 early today at 0245 UTC (10:45 p.m. EDT on Oct. 7).GOES satellites are operated by NOAA, and images and animations of GOES satellite data are created by the NASA GOES Project at NASA's Goddard Space Flight Center, Greenbelt, Md.
Because Hurricane Otto is expected to remain in an environment with light wind shear and warm waters for about 24 hours (until 11 a.m. EDT Saturday, Oct. 9), it is expected to strengthen during that time. After mid-day Saturday (eastern daylight time) Otto will run into increasing winds shear from the southwest and it will move into cooler waters. Sea surface temperatures of at least 80 degrees Fahrenheit are needed to maintain a tropical cyclone (hurricane).
Over the weekend as Otto weakens it will begin transition into an extratropical storm.
INFORMATION:
NASA sees Otto become eighth hurricane of the Atlantic season
2010-10-10
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
NASA's Mobile Mars Laboratory almost ready for flight
2010-10-10
The Sample Analysis at Mars (SAM) instrument suite has completed assembly at NASA's Goddard Space Flight Center in Greenbelt, Md., and is nearly ready for a December delivery to NASA's Jet Propulsion Laboratory (JPL), Pasadena, Calif., where it will be joined to the Curiosity rover. SAM and Curiosity are set to fly on the on the upcoming Mars Science Laboratory (MSL) rover mission scheduled for launch in the fall of 2011.
SAM will become an automated, mobile laboratory as it is carried across Mars by the rover when the mission arrives at the Red Planet in 2012. Together ...
UT Southwestern researchers create experimental vaccine against Alzheimer's
2010-10-10
DALLAS – Oct. 12, 2010 – Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.
Compared with similar so-called DNA vaccines that the UT Southwestern researchers tested in an animal study, the new experimental vaccine stimulated more than 10 times as many antibodies that bind to and eliminate beta-amyloid. The results appeared in the journal Vaccine.
Future studies will focus on determining the ...
Clue to unusual drug-resistant breast cancers found
2010-10-10
Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.
The study is published in the Oct. 8 issue of the Journal of Biological Chemistry, where it is designated a paper of the week.
Approximately 70 percent of breast cancers express the estrogen receptor. These "ER-positive" tumors usually respond to hormone-related therapies, such as tamoxifen or aromatase inhibitors. But not always.
"We ...
Progress toward first commercial repellent for East Coast's stinker
2010-10-10
WASHINGTON, Oct. 9, 2010 — Help may be on the way for millions of people on the East Coast bugged out about the invasion of stink bugs. Scientists have reported a key advance in efforts to develop the first commercial repellent for stinkbugs, which are emerging as a major nuisance to homeowners and a devastating pest to some farm crops. They identified a natural substance in a fungus that infects a common weed and found that it shows potential as the first stinkbug repellent. Their study appeared in ACS' bi-weekly Journal of Agricultural and Food Chemistry.
Hiromitsu ...
Clinical trials demonstrate effective weight loss strategies for obese and overweight adults
2010-10-10
CHICAGO -- Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.
According to background information in the papers, obesity is among the ...
Prepared meals and incentivized weight-loss program for obese and overweight women
2010-10-10
In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 – 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010.
The women were randomized into three intervention groups: in-person, center-based (167 women) or telephone based (164 women) weekly one-to-one weight loss counseling, including free-of-charge prepackaged prepared ...
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
2010-10-10
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
The study included 128 patients with advanced non-small cell lung cancer who were ...
Surgical technique relieves painful spine fractures in patients with metastatic cancer
2010-10-10
A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.
Many patients with multiple myeloma, or those whose cancer has spread beyond the initial tumor site, suffer compression fractures in their spine. This is partly because the spine is one of the most common sites for metastatic spread of the disease, making the vertebrae brittle and at risk for fractures. Widely-used cancer ...
Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
2010-10-10
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.
The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
"Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 ...
Identifying subsets of patients who will respond to subsequent lines of chemotherapy
2010-10-10
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.
Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006.
They found that the median overall survival grew progressively smaller for each successive chemotherapy ...